Ilixadencel is under clinical development by Mendus and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ilixadencel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ilixadencel overview
Ilixadencel is under development for the prevention of hepatocellular carcinoma, gastrointestinal stromal tumor (GIST), HPV-positive or HPV-negative squamous cell carcinoma of the head and neck, non-small cell lung cancer, gastric, adenocarcinoma of the gastroesophageal Junction. The drug candidate is administered intratumorally. The vaccine candidate is based on COMBIG (Combined Toll like Receptor Interferon-Gamma) platform.
The drug candidate was under development for melanoma (first and second), colon carcinoma, brain metastasis, squamous cell carcinoma of the head and neck, metastatic renal cell carcinoma (RCC), non-small cell lung cancer, gastric and gastroesophageal junction adenocarcinoma.
Mendus overview
Mendus develops novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. The company’s pipeline product include vididencel is for the treatment of acute myeloid leukemia and ovarian cancer; ilixadencel for soft tissue sarcomas; preclinical pipeline targets natural killer (NK) cell program. The company markets its products under the brand DCOne. It operates a research and development facility in Leiden, the Netherlands. The company works in partnership with academic research groups, pharmaceutical and biotech companies to develop and commercialize new therapeutics. Mendus is headquartered in Stockholm, Sweden.
For a complete picture of Ilixadencel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
